Divalproex Sodium Tablet, Delayed Release
Product Images NDC 68788-4079

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68788-4079). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Divalproex Sodium De Figure 1)

Chemical structure of divalproex sodium depicted with its molecular groups, showing the arrangement of carbon, hydrogen, oxygen, and sodium atoms forming the compound.*

FDA Label Image

Figure1 (Divalproex Sodium De Figure 2)

A bar chart comparing percentages between two study groups labeled PBO and DVPX for Study 1 (YMRS) and Study 2 (MRS). The bars show values of 26% and 60% for Study 1, and 29% and 58% for Study 2, respectively.*

FDA Label Image

Figure2 (Divalproex Sodium De Figure 3)

A line graph comparing the percentage reduction in CPS rate between divalproex sodium and placebo across different percentages of patients. The vertical axis shows the percentage reduction in CPS rate from -100% to 100%, with labeled areas for worsening, no change, and improvement. The horizontal axis represents the percent of patients from 0 to 100.*

FDA Label Image

Figure3 (Divalproex Sodium De Figure 4)

A line graph depicting percent reduction in CDRS Rate versus percent of patients for high dose and low dose treatments. The vertical axis measures improvement with higher values and worsening with lower values, ranging from -100% to 100%. Two curves compare high dose (solid line) and low dose (dashed line) responses in patients.*

FDA Label Image

Figure4 (Divalproex Sodium De Figure 5)

This bar chart compares the effects of placebo versus divalproex sodium in two separate studies, labeled Study 1 and Study 2. The vertical axis measures an unspecified outcome with values ranging from 0 to 6, showing higher values for placebo than divalproex sodium in both studies.*

FDA Label Image

Divalproex Sodium Dr 250mg (Divalproex Sodium De Figure 7)

Label for Divalproex Sodium DR 250 mg delayed-release oral tablets by Preferred Pharmaceuticals Inc. Identified as generic for Depakote DR, the label includes dosage and tablet size information, manufacturer OrBion Pharmaceuticals Pvt. Ltd., warnings, storage instructions, barcode, and bilingual (English/Spanish) dosage directions spaces. Lot number, expiration date, and product NDC fields are present but not filled.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.